Pifeltro pill image


100 mg doravirine DOR (NNRTI)

DHHS recommended as a component of initial regimen in certain clinical situations (as a component of Delstrigo, or in combination with Descovy, Truvada, Cimduo, or Temixys)
Non-Nucleoside "Non-Nuke"

Standard Dose

One tablet, once daily with or without food, in combination with other antiretroviral drugs in people taking HIV treatment for the first time (treatment-naïve) or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV viral load less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known viral substitutions associated with resistance to doravirine. Must be taken in combination with another antiretroviral(s) from a different drug class.

Approved for adults and children who weigh at least 77 pounds (35 kg).

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. No dosage adjustment necessary for mild, moderate, or severe kidney impairment or for mild or moderate liver impairment. Pifeltro has not been studied in people with severe liver impairment.
  • See package insert for more complete information on potential side effects and interactions.


Merck and Co.
(800) 672–6372



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments